Bio-Thera Reports the Initiation of P-III Clinical Trial for BAT2506 (biosimilar, golimumab)

 Bio-Thera Reports the Initiation of P-III Clinical Trial for BAT2506 (biosimilar, golimumab)

Shots:

  • The company has initiated a P-III clinical study to evaluate the efficacy and safety of BAT2506 vs Simponi in ~ 480 volunteers with PsA. Simponi is approved for moderately to severely active RA, active PsA, active AS & UC
  • BAT2506 is the 3rd proposed biosimilar of the company to enter a global P-III study
  • Bio-Thera is developing other proposed biosimilars, including a bevacizumab & tocilizumab biosimilar that have completed P-III trial and is also pursuing biosimilar versions of ustekinumab, mepolizumab and dupilumab

Click here to­ read full press release/ article | Ref: Business Wire | Image: Business Wire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post